Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney transplantation by Manook, Miriam et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/ajt.14234
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Manook, M., Kwun, J., Burghuber, C., Samy, K., Mulvihill, M., Yoon, J., ... Knechtle, S. J. (2017). Thrombalexin:
use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in a highly sensitized model of kidney
transplantation. American journal of transplantation : official journal of the American Society of Transplantation
and the American Society of Transplant Surgeons. https://doi.org/10.1111/ajt.14234
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/ajt.14234 
This article is protected by copyright. All rights reserved. 
MR. KYLE WILLIAM FREISCHLAG (Orcid ID : 0000-0002-0234-5235) 
 
Received Date : 11-Jun-2016 
Revised Date   : 04-Jan-2017 
Accepted Date : 26-Jan-2017 
Article type      : O - Original Article 
 
 
Thrombalexin: use of a cytotopic anticoagulant to reduce thrombotic microangiopathy in 
a highly sensitized model of kidney transplantation. 
 
Authors:  
 
Miriam Manook1,2, Jean Kwun1, Christian Burghuber3, Kannan Samy1, Michael Mulvihill1, 
Janghoon Yoon1, He Xu1, Andrea L.MacDonald1 , Kyle Freischlag1,Verna Curfman1, Evelyn 
Branum1, David Howell1,  Alton Brad Farris4, Richard A Smith5, Stephen Sacks5, Anthony 
Dorling5, Nizam Mamode2, Stuart Knechtle1,* 
 
 
 Department & Institution:  
1
 Duke Transplant Center, Department of Surgery, Duke University Medical Center, 
Durham, NC 27710 
2
 Renal and Transplant Department, Guy’s and St Thomas’ NHS Foundation Trust,  
3
 Division of Transplantation, Department of Surgery, Medical University of Vienna, 
Vienna, Austria 
4
 Department of Pathology, Emory University Hospital, Atlanta GA 30322 
5MRC Centre for Transplantation, King’s College, London, UK 
Corresponding author: 
Stuart J Knechtle, MD  
330 Trent Drive, DUMC Box 3512, Durham, NC 27710, U.S.A.  
Phone: 919-613-9687;  
Fax: 919-684-8716;  
E-mail: stuart.knechtle@dm.duke.edu 
 
Running title: Cytotopic anti-coagulation in transplantation 
Abbreviations:  
 
ABMR  Acute Antibody Mediated rejection 
EC  Endothelial Cell 
HLL  Hirudin-like peptide 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
IBMIR  Instant Blood Mediated Inflammatory Reaction 
MAHA  Microangiopathic Haemolytic Anaemia 
NPI  Neonatal Porcine Islets 
TEG  Thromboelastography 
TLN  Thrombalexin 
TMA  Thrombotic Microangiopathy 
 
Abstract  
 
Early activation of coagulation is an important factor in the initiation of innate immunity, as 
characterized by thrombotic microangiopathy (TMA). In transplantation, systemic anti-
coagulation is difficult due to bleeding. A novel ‘cytotopic’ agent, ‘Thrombalexin’, (TLN) 
combines a cell-membrane bound (mirystoyl tail) anti-thrombin (HLL peptide) which can be 
perfused directly to the donor organ or cells..  
Thromboelastography (TEG) was used to measure time to clot formation (r-time) in both rhesus 
and human blood, comparing TLN vs. HLL (without cytotopic tail) vs. negative-control. Both TLN 
and HLL treated rhesus or human whole blood result in significantly prolonged r-time compared 
to kaolin controls. Only TLN-treated human endothelial cells (EC) and neonatal porcine islets 
(NPI) prolonged time to clot formation. Detection of membrane-bound TLN was confirmed by 
immunohistochemistry and FACS. In vivo, perfusion of a NHP kidney TLN-supplemented 
preservation solution in a sensitized model of transplantation demonstrated no evidence of TLN 
systemically. Histologically, TLN was shown to be present up to four days after transplantation. 
There was no platelet deposition and TMA severity, as well as microvascular injury scores 
(glomerulitis + peritubular capillaritis) were less in the TLN treated animals. Despite promising 
evidence of localized efficacy, no survival benefit was demonstrated. 
 
Introduction  
Thrombotic microangiopathy (TMA) is a systemic pathological phenomenon of systemic 
thrombocytopaenia, microangiopathic haemolytic anaemia (MAHA) and microvascular 
thrombosis, with local consequences of potential end-organ damage resulting from deposition of 
microthrombi. Although primarily a thrombotic disorder, TMA is representative of the crosstalk 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved.  
between coagulation and complement activation, as part of the innate immune system (1). 
Primary TMA has a wide differential diagnosis (2). Following renal transplantation, TMA is a 
phenomenon observed in differing clinical circumstances either arising as a result of disease 
recurrence, such as in haemolytic uraemic syndrome (HUS, and atypical HUS), or in antibody 
mediated rejection(3). Histological features of TMA in the transplanted organ range from acute 
fibrin thrombi and endothelial swelling to membranoproliferative lesions, segmental glomerular 
sclerosis, arteriolar hyalanosis, intimal fibrosis and laminated hypertrophy of the arteriolar walls 
(4, 5). In the revised Banff classification from 2013, TMA is one of the histological markers of 
acute tissue injury required for a diagnosis of acute/active antibody mediated rejection 
(ABMR)(6, 7). Since TMA is one of a number of features of ABMR, and not seen in all cases, it 
may be difficult to identify recipients at risk of developing TMA, although it is more frequent in 
highly sensitized models of transplantation (8). Prophylactic treatment at the time of 
transplantation to prevent TMA is difficult with conventional anti-coagulation therapy (heparin, 
coumarins, warfarin) due to the risk of bleeding in the post-operative setting and the 
requirement for systemic treatment and repeated dosing. A localized anticoagulant therapy is 
therefore highly desirable. 
Thrombalexin (TLN) is a novel cytotopic anticoagulant suitable for localized treatment of donor 
organ, tissues or cells prior to transplantation.  It combines a hirudin-like peptide (HLL, based on 
the thrombin inhibitor, hirudin), with a mirystoyl tail which inserts directly into the cell membrane. 
TLN inhibits thrombin activation only in the location where it is applied. Previously, variants of 
the compound have been used in a hepatocyte model, with the goal of overcoming instant blood 
mediated inflammatory reaction (IBMIR)(9). Thrombalexin has also been tested to treat donor 
organs in a highly sensitized rodent transplant model wherein it was shown to increase survival 
when compared to no treatment(10). The mechanism of plasma membrane localization makes 
Thrombalexin ideally suited for treatment of both solid organ and cell-based transplantation. 
Here we report our findings of both in vitro and in vivo  efficacy of Thrombalexin, in a highly 
sensitized rhesus model of organ transplantation. 
Materials and Methods  
Cells, plasma, and blood preparation 
Citrated blood samples from healthy human volunteers and non-human primates were approved 
by Duke University institutional review board (IRB Pro00062495) and Duke Institutional Animal 
Care and Use Committees (IACUC A209-15-07). Platelet poor plasma was obtained from 
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citrated whole blood samples, which were spun for 15m at 2700g. Following this, the 
supernatant was further spun for 15 min at 2700g before being frozen (-20) prior to use (TLN 
detection & ELISA). Wild-type neonatal porcine islet (NPI) and primary human aortic endothelial 
cells (EC) were cultured as per supplemental methods. 
 
Animal selection and care 
Specific pathogen-free, 3 to 6 year old male rhesus macaques (Macaca mulatta) from Alpha 
Genesis Inc. (Yemassee, SC) were MHC genotyped by deep sequencing at the Genetics 
Services Unit, Wisconsin National Primate Research Center, Madison, WI. Donor-recipient pairs 
were selected by choosing maximal disparity for MHC class I & II. As described previously, 
donor-recipient pairs underwent two serial skin transplants prior to kidney transplantation. All 
animals received depletional induction with anti-CD4 & anti-CD8 mAbs (CD4R1 & M-T807R1 
NHP Reagent Resource, Mass Biologics, MA) at the time of transplant followed by maintenance 
therapy with tacrolimus, mycophenolate mofetil and prednisolone (8). Rhesus monkey kidneys 
not required for implantation were retrieved as for a donor nephrectomy, flushed slowly with 5ml 
of UW (University of Wisconsin) perfusion solution, before being flushed with Thrombalexin 
(TLN) for ex-vivo detection by IHC, following the slow TLN flush, a further 5ml flush of UW was 
given to remove unbound compound. All medication and procedures were conducted in 
accordance with Duke Division of Lab Animal Resources (DLAR), Yerkes National Primate 
Center, (Atlanta, GA) and the National Institutes of Health (Bethesda, MD) guidelines after 
approval by both Duke University (Durham, NC) and Emory University (Atlanta, GA) Institutional 
Animal Care and Use Committees. 
 
Thrombalexin (TLN; PTL060) infusion 
Thrombalexin (TLN or PTL060, TLN-3) compound consists of membrane-localizing agent 
(mirystoyl tail) attached to hirudin-derived sequence, ‘HLL’ (a hirudin-like molecule which binds 
both to the active site of thrombin, and has an exosite which interacts with fibrinogen, see 
Figure 1A). A stock solution was prepared, 1mg/ml to give a concentration of 2 μM. A 
compound, (HLL or PTL011) with the hirudin-like molecule but no cytopic tail was used as a 
control, which was also prepared to a 2μM stock solution. Both agents were generously 
supplied by Dr R. Smith, MRC Centre for Transplantation, King’s College, London, and were 
synthesized by Almac Sciences, Craigavon, UK.  Following donor nephrectomy, all kidneys 
were perfused via the renal artery with 5-8mls of University of Wisconsin (UW) perfusion 
solution until the effluent from the renal vein was clear. Thrombalexin treated animals received 
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TLN 4uM (500 ul of stock solution (1mg/ml) of PTL060, diluted in 5mls of UW, followed by an 
additional flush of UW solution (5ml) to remove any unbound TLN. 
 
Flow cytometric detection of Thrombalexin (PTL060)  
FACS detection of TLN in whole blood or plasma (human or rhesus), EC and PBMC was 
performed using TLN-specific primary antibody (RICS2, 1:500, gift from R. Smith, King’s 
College) and secondary antibodies (goat anti-mouse FITC, AbD Serotec). For full details see 
Supplemental Methods. Flow cytometry was performed on BD LSRFortessa x20 and analyzed 
using FlowJo (Tree Star, San Carlos, CA) software. 
 
Thromboelastography (TEG)   
Thromboelastography (TEG, Haemonetics, IL) uses mechanical motion to provide a 
quantification of whole blood coagulation, where r-time represents the time to clot initiation and 
is a reflection of coagulation factor activity(11). TEG was used to assess the direct effect of TLN 
(or controls) on whole blood (human or rhesus), TLN (or control) treated cells, as well as post-
transplant evidence of changes in time to clot formation. For full details see Supplemental 
Methods. 
 
IHC and Immunofluorescence staining for Thrombalexin 
Tissue sections were submitted for formalin fixed paraffin embedding (FFPE). And stained for 
Haematoxylin & Eosin, C4d (American Research Products), Inc, Whaltham, MA), CD61 (human 
platelet glycoprotein IIIa, Sigma-Aldrich, USA) by the core histopathology research lab (Duke 
University, Durham, NC). Interpretation of immunohistochemistry specimens was performed by 
Dr David Howell (Duke University, Durham) this included TMA & CD61 scoring (1 = mild; 2 = 
moderate; 3 = severe, 0 = none). Dr Brad Farris (Emory University, Atlanta) undertook blinded 
review of Banff scoring at a secondary institution. For a TLN detection, tissue sections were 
embedded in OCT, rapidly frozen and maintained at -80 degrees. Frozen section slides were 
fixed in cold acetone for 20 minutes and air dried. After autoquench and blocking steps, primary 
staining was performed with RICS2 (1:100, primary antibody raised in mouse against PTL060, 
gift from R Smith) and a secondary FITC ab (goat-anti-mouse FITC, AD Serotec).  For full 
details, see Supplemental methods. For detection of PTL060 on NPI, treated NPI were 
resuspended in FACS buffer (2% FBS in PBS), and treated with primary (RICS, 1: 500) and 
secondary antibody (goat anti-mouse FITC, AbD Serotec, 1: 200) before being added 
transferred to a slide, using a Cytospin machine. For full details, see Supplemental methods.  
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Microscopy was performed on a Leica DMRA2 Compound Microscope with OpenLab Software. 
10x and 20x objectives were used in conjunction with the following fluorescent cubes: DAPI: UV 
excitation (Ex. DAPI/Hoechst), HQ:R/Dil: Green excitation (Ex. Rhodamine RITC, Dil and HQ:F: 
Blue excitation (Ex. FITC). Digital images were captured using Volocity software.  Confocal 
imaging was performed on a Leica SP5 confocal microscope. 
 
ELISA analysis of C3a, C4d and TCC (C5b-9) 
For quantitative analysis, Enzyme linked immunoassays (ELISAs) were performed on 
commercially available kits, according to manufacturers instructions: serum samples were 
tested for C3a (MicroVue, Quidel, San Diego); C4d (MicroVue, Quidel, San Diego); SC5b-9 
(MicroVue, Quidel, San Diego). Plasma samples were tested for TAT (Thrombin-anti-Thrombin, 
Enzygnost, TAT, Siemens); Asserachrom vWF:Ag (Diagnostica Stago,  NJ ,USA). Limited 
control plasma samples (n = 1) were available for analysis.  
 
Statistical analysis 
All data are presented as mean ± standard deviation (error bars in graphs) or as otherwise 
indicated. Sample comparisons of different animals and/or time points were achieved by two-
tailed (unpaired) t- test in normally distributed data. In case of unequal variances we used 
Welch’s t-test (15). For survival analysis we used the Kaplan-Meier method and log-rank test. 
Values of p<0.05 were considered to be statistically significant. We used Prism 6.0 (GraphPad 
Software, San Diego, CA) 
 
Results (1123) 
Detection of cell membrane-bound Thrombalexin (PTL060) in whole blood 
To confirm the binding of TLN to cell membranes, whole blood (NHP and human) was spiked 
with TLN (2μM, 500μM, 125μM, 31.25μM, 7.8μM,1.94μM, 0.4μM, 0.1μM). As shown in Figure 
1B and C, TLN was detected by RICS2 mAb in both NHP (n=6), and human blood (n=6). 
Membrane bound TLN is detectable at very low levels (~0.1μM, p<0.05), which allows for 
systemic detection of the compound. Time to clot formation, was assessed by 
Thromboelastography (TEG). Citrated blood was treated with TLN (PTL060), HLL (PTL011) or 
control and time to clot initiation (r-time) measured. Interestingly, rhesus blood showed a 
reduced time to clot initiation, compared to human blood, indicating greater thrombogenic 
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potential of NHP blood. When added directly to whole blood, both PTL060 and PTL011 
prolonged the r-value in both NHP (Figure 2A) and human blood (Figure 2B), indicating 
anticoagulant effect compared to control. To demonstrate membrane binding of Thrombalexin, 
RICS2 mAb was used to detect PTL060 after endothelial cell (EC) treatment with PTL060, 
PTL011 or PBS alone, (Figure S1). PTL060 alone is detectable on EC after treatment and 
washing. NPIs are not amenable to flow detection without first being lysed, hence the 
immunofluorescent method of detection. Similarly, evidence of PTL060 binding to NPI is 
demonstrated in compared to control or PTL011 treatment (Figure S1). 
 
Prolonged coagulation time by cell-bound Thrombalexin (PTL060) on Endothelial Cells 
and Neonatal Porcine Islets 
To confirm the effect of cells incubated with Thrombalexin, r-time of human blood was 
measured with human endothelial cell (EC) alone, PTL011 incubated EC, and PTL060 
incubated EC, as well as NPI. PTL060 incubated EC significantly increased r-time while PTL011 
incubated EC did not prolonged the coagulation time compared to EC control (Figure 2C).  
Compared to PBS controls, ECs themselves shorten r-time, indicating a pro-thrombotic effect of 
EC controls (data not shown), this effect was reversed by PTL060 treatment. Similar findings 
were replicated using wild type porcine NPI alone, compared to PTL060 or PTL011 (Figure 2D). 
It should be noted that, compared to human EC in human blood, porcine NPI alone induce a 
shorter time to clot initiation in human blood.  
 
Detection of Thrombalexin (TLN) after kidney transplantation and reperfusion 
Thrombalexin is able to bind to kidney endothelium following ex-vivo perfusion within 
preservation solution.  We perfused NHP kidneys with UW solution alone, UW solution 
supplemented with PTL060 (2μM, 4μM and 8μM) and UW solution supplemented with PTL011 
(4μM) and performed immunohistochemistry. After 1 hour ex-vivo, we detected RICS2 staining 
only from the PTL060 infused kidneys. The RICS2 staining patterns changed overtime: 
deposition was predominantly within the glomeruli at 1hr post infusion but detected in tubular 
area at 72 hr post-infusion (Figure S2).  
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As a membrane-localising anticoagulant, one of the primary safety concerns in using TLN was 
the possibility of systemic elution, resulting in an increased bleeding risk. We confirmed that 
there is no detectable TLN in circulation by flow cytometry using RICS2 antibody (Figure 3A), 
either in cell bound (whole blood), or in plasma (Figure 3B, detected by secondary PBMC 
capture). To evaluate its systemic effect, we performed TEG with whole blood and plasma 
samples from untreated and TLN-treated animals. As shown in Figure 3C, at 1-hour post-
transplant samples from all animals show a variable prolonged coagulation time, although it 
should be noted that per our operative protocol, all animals receive IV heparin sulfate (100-200 
units/kg) shortly before explantation of the donor kidney. Surgically, no difference in anastamotic 
bleeding was observed between TLN treated and untreated animals. 
All TLN treated donor kidneys were perfused with TLN (4uM) in UW-solution, and received a 
secondary UW flush to eliminate any unbound TLN prior to implantation. Kidney biopsies from 
TLN treated animals, taken post reperfusion, were compared to those of untreated animals. TLN 
treated animals showed consistently positive TLN staining in the graft (Figure 3D), which was 
visible on post-transplant day 4 and still positive by POD9 (Data not shown). These data 
suggest that the tested concentration of TLN (4uM) with UW-solution localizes to the graft but 
does not induce systemic anti-coagulation.   
 
The impact of localised anti-coagulation on histological evidence of AMR 
Previously, we reported that early antibody-mediated rejection (AMR) in the sensitized rhesus 
after kidney transplantation was present, with half of the animals demonstrating 
histopathological evidence of TMA within the transplanted kidney within the first week post-
transplant(12). We hypothesized that coagulation induced by donor-specific antibody (DSA) 
initiates TMA and thereby induces AMR. Interestingly, TLN treatment (n=3) did not prolong graft 
survival compared to all untreated controls (controls n = 7, Figure 4A). In order to investigate 
the effect of TLN on histological evidence of TMA, time matched controls (early rejectors, n = 4, 
graft survival: 1, 7 and 8 days) were compared to the TLN treated monkeys (n=3, graft survival: 
4, 7 and 9 days). TLN treated animals showed significantly reduced (p=0.03) microvascular 
inflammation scores (MVI = glomerulitis, g score + peritubular capillaritis, ptc score; Figure 4B) 
and a trend of reduced C4d deposition in the graft (Figure 4C). Thus total Banff 2013 AMR 
scores were reduced in TLN-treated animals (Table 1), although this did not reach significance. 
TMA was also not entirely eliminated in the TLN treated group but it showed strong trend of 
reduction compared to the early rejector controls (p = 0.07; Figure 4D), platelet deposition – 
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measured by CD61 staining – was also reduced in the treated group, compared to controls, as 
was fibrinogen staining by immunofluorescence (Figure 4E). 
 
Systemic coagulation factors and complement activation after TLN treatment 
Systemic haemoglobin levels and circulating platelet counts were not different between groups 
(Figure 5A). These data suggest that TLN reduces intragraft thrombosis but it does not alter 
any systemic effects - anemia or thrombocytopaenia - seen with systemic TMA. In order to 
demonstrate the efficacy of thrombin blockade by thrombalexin, we measured circulating vWF 
levels, as well as thrombin-anti-thrombin (TAT) complexes. (Figure 5B), no difference in 
circulating vWF was seen in treated animals, compared to untreated control, however there was 
a trend for reduced plasma TAT levels in the early post-operative course of the TLN treated 
animals, suggesting effective thrombin inhibition, however these data should be interpreted with 
caution in view of the limited availability of control plasma samples. 
 
The role of thrombin in complement activation has been identified(13). To evaluate whether the 
complement activation cascade was affected by targeting thrombin via Thrombalexin, we 
measured serum C3a, C5b-9, C4d, and MBL. In general, there was a trend for reduced 
evidence of complement activation products in the first 24hours post-transplant in the TLN 
treated group, which was most evident, but not significant for serum C3a on day 1 (p=0.07) 
(Figure 5C). 
 
Discussion  
The use of an anticoagulant, in the form of anti-thrombin, to prevent TMA is a novel application. 
TMA is a poorly described phenomenon post kidney transplantation, although clinicians involved 
with positive crossmatch (HLAi) are familiar with this aggressive phenotype of AMR, which may 
necessitate dramatic intervention in order to prevent acute graft loss in the early post-operative 
period(14). TMA is a descriptive term, for the observed clinical presentation of microangiopathic 
haemolytic anaemia (MAHA), thrombocytopaenia and microvascular thrombosis occurring as a 
result of endothelial cell activation. It has a range of predisposing hereditary and acquired 
underlying causes, which are important to distinguish with respect to optimal treatment(15, 16). 
In renal transplantation, de novo histological evidence of TMA was found to be most commonly 
associated with C4d positive AMR (55%), of whom 84% had a high PRA. TMA is often 
considered to be a complement mediated disease(17), however it more accurately represents 
the interface between complement and coagulation(1). 
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The use of complement inhibition in the setting of highly sensitized kidney transplantation has 
gained considerable interest with the advent of anti-C5 inhibition with Eculizumab. Initial results 
in reducing AMR in highly sensitized kidney transplant recipients were very promising(18), and 
many case reports of the ability of complement inhibition to reverse severe AMR demonstrate 
great benefit to salvage grafts(19), although this is in the absence of long-term benefit(20), and 
may therefore represent the ability of complement inhibition to reverse early AMR features, 
which are associated with TMA. 
Systemic anticoagulation has, for the most part, been avoided in the immediate post-operative 
period in kidney transplantation, as a result of the potential for increased bleeding risk, hence 
the demonstration of no systemic elution of drug, or change in time to clot formation (Figure 1). 
Alternative means to control the thrombotic process of TMA through inhibition or down 
regulation of coagulation are therefore of interest. Recombinant soluble thrombomodulin (TBM) 
– a co-factor of thrombin important for the down regulation of coagulation and inflammation -  
has been used to treat TMA in the setting of liver transplantation(21). The manipulation of the 
coagulation system has also been used in xenotransplantation, as exogenously administered 
coagulation factors (human prothrombin concentrate complex, or recombinant FVIIa)(22). 
Interestingly, the genetic manipulation of TBM expression on cells within the transplanted organ 
has shown promise in both mitigating the systemic thrombocytopaenia associated with TMA in 
xenotransplantation(23), as well as abrogating the activation of complement (24).  
Our hypothesis was that TLN, as a topical anti-thrombin agent, would provide local protection of 
the kidney, or treated cells from the effects of thrombosis (Figure 2), as well as mitigate 
complement activation and, potentially down regulate inflammation and graft infiltration with 
adaptive immune cells. Thrombin itself has a role in both primary haemostasis –with respect to 
platelet activation, and secondary haemostasis, in which fibrin is crosslinked to form a stable 
haemostatic clot, which is later degraded by fibrinolysis. Previously, bivalirudin, a synthetic 
analog of hirudin currently in use in cardiac surgery, which is most analogous to the active 
element of TLN, has been demonstrated to decrease thrombin-induced platelet activation(25). 
The importance of platelet deposition in TMA, has previously been demonstrated with CD61 
staining of platelets which was positive in TMA induced by CNI toxicity in kidney transplant 
recipients(26). In our study, the absence of platelet deposition, as demonstrated by the lack of 
CD61 positivity in the TLN treated kidney grafts supports a biological effect of thrombin inhibition 
with TLN to prevent platelet activation and deposition. Additionally, histology clearly 
demonstrated less fibrin deposition and a less histologically severe form of TMA (Figure 4). 
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The effect of thrombin on complement activation is currently a field of active study. It has been 
recognized that thrombin is an activator of complement at the level of C3 however, in addition, 
thrombin has also been shown to be able to cleave C5 directly, independent of C3 (27), In our 
model, serum measurements of complement activation products, principally C3a showed a 
trend for lower levels in the immediate post-operative period (Figure 5), however this was a 
transient observation. In the kidney, evidence of complement activation, in the form of C4d 
deposition was somewhat lower (p = 0.09) in treated vs untreated animals, but this not 
significant. In addition, there was no histological difference in graft infiltrating cells, T-cell (CD3, 
CD4) or B-cell (CD20) (data not shown). Taken together, these data indicate a possible effect of 
thrombin-inhibition on complement activation, although this is not conclusive. 
The lack of survival benefit in TLN treated animals, compared to controls, contrasts with 
previous findings in a sensitized rat model(10). This is likely to be attributable to a number of 
factors. Firstly, although a survival benefit in the rat model was demonstrated, all survival times, 
in the absence of any immunosuppression, were short: TLN increased the MST in the rat model 
from 1.5d to 5.1. MST in our TLN treated group was 6.6 days, compared to 4.25d in the early 
rejector control group, and 18.7d with all controls. This may represent the dwell time of TLN on 
the cell-membrane target, and therefore period of efficacy.  
Secondly, it may be a consequence of underdosing, although drug elution experiments (data not 
shown) suggest that effluent from the renal vein directly after TLN administration is positive for 
TLN after 4uM dosing. Alternatively, the expression of the compound on the cell membrane is 
insufficient to provide activity, either as a consequence of the dwell time on the cell surface, or 
as a result of cellular uptake. Repeated dosing of TLN is not possible, due to the route of 
administration arterially to the organ itself.  
In present form the role of this compound remains to be established, although isolated treatment 
of the transplanted organ is a pragmatic option, particularly in light of the new role of ex-vivo 
normothermic perfusion treatments. A potential application of TLN may be, as Parajuli et al. 
advocate, as part of preventative strategies for patients at increased thrombotic risk (ie. Anti-
phospholipid antibodies protein C & S deficiencies etc), this may be a protective strategy in the 
first 24 hours post-transplant (28) that avoids the management difficulties of post-operative 
anticoagulation. 
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Further study of the interactions between coagulation and complement may yield further 
evidence which would support combination therapy with Mirococept (cytotopic C3-convertase 
inhibitor) in the perioperative setting, however these data are demonstrate promising efficacy, 
safety and detection of a novel agent within a large animal model.  
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Figure legend 
 
Figure 1. A. Schematic illustration of the structure and binding site of Thrombalexin (PTL060; 
TLN). Thrombalexin is anchored to the cell membrane with a misorystoyl tail, and prevents 
activation of Thrombin (Factor IIa) via inhibition of both the active and exo-sites. Detection of 
Thrombalexin using RICS2 mAb (mouse anti-Thrombalexin), in both rhesus (B) and human (C) 
whole blood. 
 
Figure 2. Efficacy of Thombalexin (PTL060; TLN). A. Thromboelastography (TEG) using rhesus 
whole blood comparing adding TLN or HLL (PTL011, active Hirudin-like molecule) directly to 
blood, compared to kaolin control. B. TEG using human whole blood comparing kaolin control, 
Thombalexin (PTL060; TLN) or HLL (PTL011). C. TEG demonstrating efficacy of Thrombalexin 
treated EC, compared to HLL in prolonging time to clot initiation (r time, mins) compared to EC 
alone. PBS alone (no cell suspension) controls in black are shown for representative 
comparison. D. TEG demonstrating efficacy of Thrombalexin treated NPI, compared to HLL in 
prolonging time to clot initiation (r time, mins) compared to NPI alone. NS>0.05, *p<0.05, 
**p<0.01, and ***p<0.001. PBS alone (no cell suspension) controls in black are shown for 
representative comparison. 
 
Figure 3. Systemic and In-situ detection of Thrombalexin (TLN) in kidney following 
transplantation A. Systemic detection of TLN following transplantation of a kidney infused with 
TLN at the time of retrieval in rhesus whole blood using RICS2 mAb. B. Systemic capture of 
TLN following transplantation of a kidney infused with TLN at the time of retrieval from rhesus 
plasma using an alternative source of cells (rhesus PBMC) & RICS2 mAb. C. Post-
transplantation TEG of rhesus whole blood. D. Post-transplant Immunofluoresence 
demonstrating the presence of Thombalexin (TLN) in 1hr post-reperfusion biopsy, and terminal 
kidney samples in TLN treated animals, compared to untreated controls. 
 
Figure 4. Post-transplant survival and histology after Thrombalexin (TLN) treatment of the 
donor kidney. A. Survival of TLN (4uM) treated kidneys, compared to untreated controls B. 
Banff (2013) Microvascular inflammation scores (glomerulitis + peritubular capillaritis) between 
time matched controls and TLN treated kidneys.  
C. Banff (2013) C4d deposition between time matched controls and TLN treated kidneys. D. 
Histological thrombotic microangiopathy (TMA) scores between time matched controls and TLN 
treated kidneys. E. Histological evidence of platelet (CD61) deposition between time matched 
controls and TLN treated kidneys and representative histological fibrinogen deposition between 
time matched controls and TLN treated kidneys. NS>0.05 and *p<0.05. 
 
Figure 5. Post-transplant systemic evidence of coagulation & complement inhibition. A. 
Systemic haemoglobin & platelet levels of TLN treated animals, compared to controls. B. 
Systemic (plasma) detected von Willebrand Factor (vWF) & Thrombin-anti-Thombin complexes 
(TAT) of TLN treated animals, compared to controls. C. Systemic detected complement 
products: C3a, C5b-9, C4d containing activation fragments & Mannose Binding Lectin (MBL) in 
TLN treated animals, compared to controls. *p<0.05. 
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Supporting Information 
 
Additional Supporting Information may be found in the online version of this article. 
 
Supplemental Methods 
 
Figure S1. A. Detection of membrane bound on EC after incubation with Thrombalexin 
(PTL060; TLN), HLL (PTL011) or PBS control, using PTL060 detection by RICS2 mAb by flow 
cytometry. B. Immunofluoresence detection of Thrombalexin binding to neonatal porcine islets 
(NPI) using RICS2 mAb compared to HLL or control.  
 
Figure S2. In-situ detection of Thrombalexin. A. Immunofluoresence demonstrating the 
presence of Thrombalexin (PTL060; TLN), at various concentrations (2mM, 4mM and 8mM) at 
1hr post-perfusion, compared to HLL (PTL011, 4mM). B. Immunofluoresence demonstrating the 
presence of Thombalexin (PTL060; TLN) following infusion of 4mM solution after 1hr, 24hrs, 
48hrs and 72 hrs. 
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Table 1: Pre-transplant T-cell and B-cell FXCM, survival and antibody mediated rejection histology scoring 
(Banff 2013) for early rejecting control NHP who experienced thrombotic microangiopathy (TMA), compared 
to Thrombalexin (TLN) treated animals. Following 2 sensitising skin transplants, all animals received 
induction therapy with CD4+mAb & CD8+mAb depletion at the time of kidney-swopping transplantation, in 
addition to triple therapy maintenance immunosuppression (tacrolimus, steroid & mycophenolate mofetil) 
post transplant. 
 
 
 
 
 
 
  
Treatment Animal DSA T Cell 
XM (MFI 
ratio) 
DSA B Cell 
XM (MFI 
ratio) 
Survival 
(days) 
AMR Score (Banff) Histology 
Pre-Tx Pre- Tx g ptc c4d total   
Control: 
CD4/CD8 
DW03 27.5 9.6 1 2 2 2 6 AMR, TMA hyperacute
Control: 
CD4/CD8 
GB5C 5.3 9.7 7 3 0 2 5 AMR, TMA 
Control: 
CD4/CD8 
FE42 20.9 18.1 8 3 1 2 6 AMR, TMA 
Control: 
CD4/CD8 
RBb15   
12.08 
 
10.3 
1 3 1 2 6 TMA, AMR, diffuse cortical 
necrosis 
Thrombalexin: 
CD4/CD8 + 
TLN (4uM) 
FG2M 
 
2.7 3.6 9 2 1 2 5 Pyelonephritis/CMV
Thrombalexin: 
CD4/CD8 + 
TLN (4uM) 
H354  
 
 
19.8 
 
3.0 
4 2 0 1 3 TMA, AMR 
Thrombalexin: 
CD4/CD8 + 
TLN (4uM) 
DX6P 
 
 
5.3 
 
4.7 
6 1 1 1 3 Non-specific, possible AMR
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